| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/1744666X.2016.1178574 |
| P698 | PubMed publication ID | 27097787 |
| P2093 | author name string | Javier Molina-Infante | |
| Pedro Luis Gonzalez-Cordero | |||
| Raul Prados-Manzano | |||
| P2860 | cites work | The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. | Q53650077 |
| Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies | Q26860824 | ||
| Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment | Q28252340 | ||
| Common variants at 5q22 associate with pediatric eosinophilic esophagitis | Q28943383 | ||
| Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease | Q34003041 | ||
| Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model | Q34394199 | ||
| Dose-dependent food allergy induction against ovalbumin under acid-suppression: a murine food allergy model | Q34394223 | ||
| The role of protein digestibility and antacids on food allergy outcomes | Q34394239 | ||
| Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. | Q34488489 | ||
| Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells | Q34490922 | ||
| GWAS identifies four novel eosinophilic esophagitis loci | Q34545768 | ||
| Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study | Q34614300 | ||
| Advances in clinical management of eosinophilic esophagitis | Q34619973 | ||
| Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation | Q34892555 | ||
| Molecular, genetic, and cellular bases for treating eosinophilic esophagitis | Q35537424 | ||
| Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study | Q36072597 | ||
| Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. | Q36553408 | ||
| Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis | Q36578734 | ||
| Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis | Q37562835 | ||
| Eosinophilic esophagitis: updated consensus recommendations for children and adults | Q37863307 | ||
| ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). | Q38097271 | ||
| Review article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis | Q38105162 | ||
| Safety of long-term PPI therapy | Q38133683 | ||
| Management guidelines of eosinophilic esophagitis in childhood. | Q38174753 | ||
| Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies | Q38618644 | ||
| Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis | Q38629162 | ||
| Oesophageal baseline impedance values are decreased in patients with eosinophilic oesophagitis | Q40142386 | ||
| High Prevalence of Response to Proton-pump Inhibitor Treatment in Children With Esophageal Eosinophilia. | Q40379873 | ||
| Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. | Q41163839 | ||
| Surgical Elimination of the Gastric Digestion by Roux-en-Y Gastric Bypass Impacts on Food Sensitisation-a Pilot Study | Q41287874 | ||
| Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium | Q42454562 | ||
| The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor | Q42622855 | ||
| Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in BALB/c mice | Q44588814 | ||
| Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. | Q45966172 | ||
| Acid hypersensitivity in patients with eosinophilic oesophagitis | Q46224681 | ||
| Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia | Q46374558 | ||
| Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. | Q53328595 | ||
| Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. | Q53493586 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 945-952 | |
| P577 | publication date | 2016-04-21 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | The role of proton pump inhibitor therapy in the management of eosinophilic esophagitis | |
| P478 | volume | 12 |
| Q56350244 | New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting | cites work | P2860 |
Search more.